Thus, selective inhibition of the JAK2 pathway improves the function of CD19 CAR-T cells against B-ALL, regardless of the JAK2 mutation status, which holds promise for improving the prognosis of refractory B-ALL. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.